Corticosteroids and aldose reductase inhibitor Epalrestat modulates cardiac action potential via Kvβ1.1 (AKR6A8) subunit of voltage-gated potassium channel
- 141 Downloads
We previously demonstrated the role of Kvβ1.1 subunit of voltage-activated potassium channel in heart for its sensory roles in detecting changes in NADH/NAD and modulation of ion channel. However, the pharmacological role for the association of Kvβ1 via its binding to ligands such as cortisone and its analogs remains unknown. Therefore, we investigated the significance of Kvβ1.1 binding to cortisone analogs and AR inhibitor epalrestat. In addition, the aldose reductase (AR) inhibitor epalrestat was identified as a pharmacological target and modulator of cardiac activity via binding to the Kvβ1 subunit. Using a combination of ex vivo cardiac electrophysiology and in silico binding, we identified that Kvβ1 subunit binds and interacts with epalrestat. To identify the specificity of the action potential changes, we studied the sensitivity of the action potential prolongation by probing the electrical changes in the presence of 4-aminopyridine and evaluated the specificity of pharmacological effects in the hearts from Kvβ1.1 knock out mouse. Our results show that pharmacological modulation of cardiac electrical activity by cortisone analogs and epalrestat is mediated by Kvβ1.1.
KeywordsKvβ subunit Heart Aldo–keto reductase Cortisone
Authors acknowledge the grant support received from NIH HL102171 to (SMT).
Compliance with ethical standards
Authors have no disclosures.
All institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the Institutional Animal Care and Use Committee at the University of South Florida (Tampa, FL, USA) at which the studies were conducted.
- 8.Tur J, Chapalamadugu KC, Padawer T, Badole SL, Kilfoil PJ 2nd, Bhatnagar A, Tipparaju SM (2016) Deletion of Kvbeta1.1 subunit leads to electrical and haemodynamic changes causing cardiac hypertrophy in female murine hearts. Exp Physiol 101:494–508. doi: 10.1113/ep085405 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R (1995) Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 49:269–277. doi: 10.1016/0753-3322(96)82642-4 CrossRefPubMedGoogle Scholar
- 13.Tang WH, Kravtsov GM, Sauert M, Tong XY, Hou XY, Wong TM, Chung SK, Man Chung SS (2010) Polyol pathway impairs the function of SERCA and RyR in ischemic-reperfused rat hearts by increasing oxidative modifications of these proteins. J Mol Cell Cardiol 49:58–69. doi: 10.1016/j.yjmcc.2009.12.003 CrossRefPubMedGoogle Scholar
- 20.Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:364–389. doi: 10.1210/jc.2015-1710 CrossRefPubMedGoogle Scholar